<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349010</url>
  </required_header>
  <id_info>
    <org_study_id>009-10-802-01</org_study_id>
    <nct_id>NCT01349010</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Control, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Imported Probucol in Hyperlipidemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of imported Probucol in&#xD;
      hyperlipidemia patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo control, multi-centre clinical study in&#xD;
      hyperlipidemia patients.&#xD;
&#xD;
      Enrolled subjects will be randomized to the treatment group or control group, and receive&#xD;
      Probucol or placebo continuously for 8 weeks; Treatment group: Imported Probucol 250 mg (1&#xD;
      tablet) bid. p.o Control group: Placebo 1 tablet bid. p.o&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TC and LDL-C</measure>
    <time_frame>8-week</time_frame>
    <description>Changes of TC and LDL-C from the baseline after 8-week treatment;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxLDL and MCP-1</measure>
    <time_frame>8-week</time_frame>
    <description>Changes of oxLDL and MCP-1 from the baseline after 8-week treatment;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Arm: Placebo 1 tablet bid. p.o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probucol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>250mg (1 tablet) bid. p.o for 8 weeks</description>
    <arm_group_label>Probucol</arm_group_label>
    <other_name>Lorelco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet bid. p.o for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing Informed Content Form;&#xD;
&#xD;
          2. Age &gt;= 20 (the age at the time of signing ICF; both gender);&#xD;
&#xD;
          3. hyperlipidemia patients who meet the following criteria:&#xD;
&#xD;
               -  4.14 mmol/L (160mg/dL) =&lt; LDL-C (Serum low density lipoprotein-cholesterol) &lt; 6&#xD;
                  mmol/L (232mg/dL)&#xD;
&#xD;
               -  TG (Serum triglycerides) &lt; 4.5 mmol/L (398mg/dL);&#xD;
&#xD;
          4. Framingham: Coronary Heart Disease 2-year risk probabilities &lt; 10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who receive antilipemic agents within 1 month prior to the pre-screening&#xD;
             period;&#xD;
&#xD;
          2. Subjects who receive Probucol within 6 months prior to the pre-screening period;&#xD;
&#xD;
          3. Coronary Heart Disease subjects;&#xD;
&#xD;
          4. Subjects being treated with cyclosporine;&#xD;
&#xD;
          5. Subjects with a history of hypersensitivity to Probucol;&#xD;
&#xD;
          6. QTc interval &gt; 450ms (male); QTc interval &gt; 470ms (female);&#xD;
&#xD;
          7. Subjects with impaired hepatic and renal function, who meet any of the following&#xD;
             abnormal value:&#xD;
&#xD;
               -  AST &gt;= 100IU/L&#xD;
&#xD;
               -  ALT &gt;= 100IU/L&#xD;
&#xD;
               -  Serum creatinine &gt;= 1.5mg/dL&#xD;
&#xD;
          8. Female subjects who are pregnant, lactating, or who plan to conceive;&#xD;
&#xD;
          9. Subjects who are considered by the investigator to be inappropriate to participate in&#xD;
             this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuiping Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sencond Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sencond Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

